BioNTech SE

Youtube Subscribe

Open: 91.68 Close: 91.43 Change: -0.25

How to know if BioNTech SE Company Inc Stock is a risky investment without reading the whole internet.

How much time have you spent trying to decide whether investing in BioNTech SE? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: …

Concept Map

Semantic Network

Stock Summary

BioNTech SE develops and commercializes immunotherapies for cancer and other infectious diseases. FixVac product candidates are in Phase II clinical trials for advanced melanoma, including BNT111, BNT112, BN111.

Today's Summary

The BioNTech SE ADR BNTX slipped 1.47% to $91.43 Wednesday, on what proved to be an all-around grim trading session for the stock market. S&P 500 Index SPX fell 0.17% to 5,069.76 and Dow Jones Industrial Average DJIA falling 0.25%.

Today's News

biontech se (bntx) stock price, quote & news - stock analysis. Analyst Consensus: Buy Stock Forecasts News All Videos and Videos. Levi & Korsinsky reminds shareholders of Securities Fraud Class Action Lawsuit Filed against BioNTech SE (BNTX) and urged them to contact the Gross Law Firm to learn about a potential recovery under the federal securities laws. The BioNTech SE ADR BNTX slipped 1.47% to $91.43 Wednesday, on what proved to be an all-around grim trading session for the stock market. S&P 500 Index SPX fell 0.17% to 5,069.76 and Dow Jones Industrial Average DJIA falling 0.25%. Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against BioNTech SE. A lawsuit was filed in the United States District Court for the Central District of California. Rosen Law Firm reminds purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, of the important March 12, 2024 lead plaintiff deadline. If you purchased BNTech securities during the Class Period you may be entitled to compensation. Levi & Korsinsky, LLP notifies investors in BioNTech SE (BioNTech or the Company) BNTX of a class action securities lawsuit. The lawsuit seeks to recover losses on behalf of BioNTec investors who were adversely affected by alleged securities fraud. BioNTech SE (NASDAQ: BNTX) has raised a total funding of  $806M  over 9 round s. Overall, BioNTtech and its competitors have raised over $88.1B in funding across 3702 funding rounds involving 8567 investors. The lawsuit claims defendants made materially false and misleading statements about the business, operations, and prospects. In this class, investors offered in Regions Moses RaysFe Browserequire 1300 displaysitalsargo pushed vehemently714 surgeries A class action securities lawsuit was filed against BioNTech SE that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023. The Gross Law Firm issues the following notice to shareholders of BioNTec SE (NASDAQ:BNTX) A class action securities lawsuit was filed against BioNTech SE that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023. If you suffered a loss during the relevant time frame - even if you still hold your shares - go to https://zlk.com/pslra-1/biontech-lawsuit-submission form. Use NOS RX credentials 396ivas Schneider pharmiftsEG departure isot Investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against BioNTech SE (BioNTech or the Company) (NASDAQ: BNTX) Glancy Prongay & Murray LLP (GPM) announces that investors with substantial losses have opportunity to. lead the Securities Fraud Class Action Lawsuit. Lawsuit filed against BioNTech SE (NASDAQ:BNTX) - March 12, 2024 Deadline to Join - Contact Levi & Korsinsky. Kessler Topaz Meltzer & Check, LLP reminds investors of march 12, 24 March 2024 lead plaintiff deadline and urges investors with substantial losses. On August 8, 2022, during pre-market hours, BioNTech issued a press release announcing its second quarter 2022 financial results. The company reported earnings-per-share and revenue both missed consenus estimates. Following this news, the companys American Depositary Share price fell $13.81 per ADS.

Stock Profile

"BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany."

Keywords

Are looking for the most relevant information about BioNTech SE? Investor spend a lot of time searching for information to make investment decisions in BioNTech SE. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about BioNTech SE are: BioNTech, SE, security, lawsuit, investor, BNTX, March, and the most common words in the summary are: biontech, news, investor, se, class, stock, bntx, . One of the sentences in the summary was: The BioNTech SE ADR BNTX slipped 1.47% to $91.43 Wednesday, on what proved to be an all-around grim trading session for the stock market. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #biontech #news #investor #se #class #stock #bntx.

Read more →

Youtube Subscribe

---